Labcorp Gets Emergency Authorization from FDA for Home Kit to Detect Monkeypox
By Denny Jacob
Labcorp received emergency use authorization from the Food and Drug Administration for its home testing kit to help detect the virus that causes monkeypox as the number of cases rise.
The laboratory services provider said Wednesday that the authorization comes amid a reported increase in monkeypox cases. There have been 511 cases reported in 2024 through March 16 compared to fewer than 300 cases reported by late March 2023, according to the Centers for Disease Control and Prevention.
The company said the Mpox PCR test home collection kit hasn't been cleared or approved by the FDA but has been cleared for emergency use under an emergency use authorization. An EUA is aimed at facilitating the use and availability of medical countermeasures needed during public health emergencies.
The test is available to physicians to order for patients 18 years or older who are suspected of monkeypox infection.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 10, 2024 07:29 ET (11:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back